Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24156421 | 0.77 | TRPM8 (0.35) | TRPM8MAPTKMT2ALMNARAB9A | |
| SCHEMBL7088876 | 0.77 | MAPT (0.39) | TRPM8MAPTPOLBKMT2ALMNA | |
| SCHEMBL23240417 | 0.77 | TRPM8 (0.35) | TRPM8MAPTKMT2ALMNARAB9A | |
| SCHEMBL13741495 | 0.76 | MAPT (0.36) | TRPM8MAPTPOLBKMT2ALMNA | |
| SCHEMBL115419 | 0.74 | MAPT (0.39) | TRPM8MAPTPOLBKMT2ALMNA | |
| SCHEMBL12219719 | 0.74 | POLB (0.37) | TRPM8MAPTPOLBLMNARAB9A | |
| SCHEMBL191457 | 0.73 | KMT2A (0.59) | MAPTKMT2ALMNASMN1; SMN2MEN1 | |
| SCHEMBL6177216 | 0.73 | GRM5 (0.38) | MAPTKMT2ATSHRMEN1HTT | |
| SCHEMBL24156631 | 0.73 | GABRA2 (0.49) | RAB9ASMN1; SMN2 | |
| SCHEMBL30824106 | 0.73 | GRM5 (0.38) | MAPTKMT2ATSHRMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662195-B2 | Protein kinase conjugates and inhibitors | CELGENE CAR LLC (BM) | 2020-05-26 | — | — | US | disclosed |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | CELGENE CAR LLC (BM) | 2017-06-22 | — | — | US | disclosed |
| US-9556426-B2 | Protein kinase conjugates and inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2478361-A2 | PROTEIN KINASE CONJUGATES AND INHIBITORS | Avila Therapeutics, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-2352827-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | Avila Therapeutics, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011034907-A2 | PROTEIN KINASE CONJUGATES AND INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010028236-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, ADK, TTK | TRPM8 4210/4885MAPT 1897/4885POLB 3741/4885 |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | CDKN1A, SERPINB1, SPR | TRPM8 4559/4885MAPT 2233/4885POLB 2548/4885 |
| US-10662195-B2 | Protein kinase conjugates and inhibitors | MAP3K20, ADK, TTK | TRPM8 4210/4885MAPT 1897/4885POLB 3741/4885 |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, PACSIN2, MAP3K9 | TRPM8 4292/4885MAPT 1666/4885POLB 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.